People · Operator
Named in public records as an officer, director or promoter · active 2009–2026 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viamet Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $35.0M | $850.1M | 2009 |
| Eldec Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $200K | $351K | 2026 |
Robert Schotzinger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Schotzinger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Garheng Kong | 1 | 16 |
| S Edward Torres | 1 | 8 |
| James Rosen | 1 | 4 |
| Douglas Reed | 1 | 4 |
| Lauren T Silverman | 1 | 3 |
| William T. White III | 1 | 3 |
| LAUREN SILVERMAN | 1 | 3 |
| Robert Tarran | 1 | 2 |
| S. Edward T. Torres | 1 | 1 |
| Neil T. Moore | 1 | 1 |
| Andrew T. Von Eschenbach | 1 | 1 |
| Neil Moore | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.